Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

Greenhalf, William; Ghaneh, Paula; P. Neoptolemos, John; H. Palmer, Daniel; F. Cox, Trevor; F. Lamb, Richard; O. Garner, Elizabeth; Campbell, Fiona; R. Mackey, John; Costello, Eithne; J. Moore, Malcolm; W. Valle, Juan; McDonald, Alexander; Carter, Ross; C. Tebbutt, Niall; Goldstein, David; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Charnley, Richard; Lacaine, F; Scarfe, Andrew; R. Middleton, Mark; Anthoney, Alan; Halloran, Christopher; Mayerle, Julia; Oláh, Attila; Jackson, Richard; Rawcliffe, Charlotte; Scarpa, Aldo; Bassi, Claudio; W. Büchler, Markus

doi:10.1093/jnci/djt347

Public

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

Published in JNCI Journal of the National Cancer Institute • Dec 3, 2013

Authors:

William Greenhalf

Paula Ghaneh

John P. Neoptolemos

Abstract

BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection. METHODS: Microarrays from 434 patients randomized to chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1/3...

Subject

Gemcitabine

Medicine

Pancreatic cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!